SCHEMBL5857748

SCHEMBL5857748

Cc1c(C(=O)Nc2ccc(C(F)(F)F)cc2)cnn1-c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.60
NPC1 O15118 10/20 0.60
RAB9A P51151 10/20 0.60
NR3C1 P04150 3/20 0.60
MET P08581 1/20 0.58
AXL P30530 1/20 0.58
MAPT P10636 1/20 0.58
PKM P14618 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HPGD P15428 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
DPP4 P27487 1/20 0.55
NPSR1 Q6W5P4 2/20 0.54
KDM4E B2RXH2 1/20 0.54
GMNN O75496 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15184951 0.80 NPC1 (0.46) CCR1NPC1RAB9ANR3C1MAPT
SCHEMBL12175284 0.80 CCR1 (0.63) CCR1NR3C1MAPTDPP4CYP3A4
SCHEMBL15185296 0.80 MAPT (0.46) CCR1NPC1RAB9ANR3C1MAPT
SCHEMBL15185413 0.80 NPC1 (0.45) CCR1NPC1RAB9ANR3C1MAPT
SCHEMBL6052278 0.79 NPC1 (0.54) CCR1NPC1RAB9ANR3C1MAPT
SCHEMBL6052118 0.79 MAPT (0.55) CCR1NPC1RAB9AMAPTPKM
SCHEMBL13485753 0.79 NPC1 (0.57) CCR1NPC1RAB9AMETAXL
SCHEMBL15185227 0.78 MAPT (0.46) CCR1NPC1RAB9ANR3C1MET
SCHEMBL15185621 0.78 NPC1 (0.44) CCR1NPC1RAB9ANR3C1MET
SCHEMBL12530166 0.78 MCHR1 (0.53) NPC1RAB9AMETAXLPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7112594-B2 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-26 US disclosed
US-7015218-B1 Amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-03-21 US disclosed
EP-1176140-B1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2004-12-29 EP disclosed
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-10-30 US disclosed
EP-1310488-A1 FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-14 EP disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof BET1, NFATC1, ARG1 CCR1 8/4885NPC1 2904/4885RAB9A 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.